Each November, we join the diabetes community to recognize Diabetes Awareness Month and World Diabetes Day on November 14th. This year, as TrialNet begins to celebrate 20 years, we share major research advances made possible by our incredible study participants and research teams around the world.
Identifying early stages of T1D
 

During this difficult time for families around the world, staying at home is vitally important to controlling the spread of COVID-19. And, we’re continually amazed and thankful to see all the ways families are finding ways to make a difference.

A message from TrialNet Chair Carla Greenbaum, M.D.

At TrialNet, the health and safety of our participants and research teams is always our top priority.

With landmark results recently announced, the Teplizumab Prevention Study is making headlines across the country. Here, Tracy Olsten shares why her daughter Mikayla decided to join the study.

Teplizumab Prevention Study Chair Kevan Herold, M.D., Yale University, presented first-of-a-kind findings showing that teplizumab delayed type 1 diabetes a median of 2 years in children and adults at high risk. Findings were also simultaneously published in the New England Journal of Medicine 

Brenda Bradfield, BSN, CDE, works on the frontlines of type 1 diabetes (T1D) research at the Barbara Davis Center for Diabetes at the University of Colorado Anschutz Medical Campus.

For most people, the onset of type 1 diabetes seems to occur suddenly, often resulting in a trip to the emergency room with life-threatening complications such as diabetic ketoacidosis (DKA). TrialNet is working to change that scenario.

TrialNet screening is free, quick, and now more convenient than ever. Our new in-home test kits provide everything you need to collect your or your family member’s blood sample in the comfort of your home.